Impact of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor on Immune-Inflammatory Responses in the Acute Phase of Ischemic Stroke.

J Inflamm Res · 2026 · PMC13138331 · PMID 42089099

Europe PMC DOI

hedged sentence

0.3160

closest p · 6.3× alpha

0.3160

boldest claim

The sentences

did not reach statistical significanceP = 0.316not close (p > 0.1)

−0.300(−0.630–0.020) mmol/L), though the between-group difference in change from baseline did not reach statistical significance ( P = 0.316).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.